Novartis

Dabrafenib (Tafinlar) is a BRAF kinase inhibitor used to treat certain melanomas, lung cancers, thyroid cancers, and other solid tumors with BRAF V600 mutations. It blocks the abnormal BRAF protein that signals cancer cells to grow and divide. It is used alone or in combination with trametinib.

Dabrafenib blocks the action of an abnormal BRAF protein found in certain cancer cells. This protein normally helps cells grow and divide, but when it

Formoterol is a long-acting beta-2 agonist bronchodilator. Inhaled twice daily, it relaxes the muscle around the airways and keeps them open, helping maintain breathing in chronic obstructive pulmonary disease.

In COPD the airways are narrowed, making breathing hard. Formoterol is an inhaled medicine that stimulates beta-2 receptors on the smooth muscle surro

Glivec (imatinib) is the pioneering tyrosine kinase inhibitor from Novartis. By blocking the abnormal BCR-ABL protein it turned chronic myeloid leukaemia from a fatal disease into a manageable one, and it also treats GIST and other kinase-driven cancers.

Chronic myeloid leukaemia is caused by a gene swap, the Philadelphia chromosome, that creates an abnormal protein called BCR-ABL. This protein acts li

Kisqali (ribociclib) is an oral CDK4/6 inhibitor from Novartis for hormone receptor-positive, HER2-negative breast cancer. With endocrine therapy it is used for high-risk early breast cancer after surgery and for advanced or metastatic disease, blocking the cell-cycle machinery cancer cells use to multiply.

Certain breast cancers depend on hormones and on the enzymes CDK4 and CDK6 to keep their division cycle turning. Ribociclib, taken by mouth, specifica

Entresto combines sacubitril, a neprilysin inhibitor, with valsartan, an angiotensin II receptor blocker. From Novartis, it reduces the risk of cardiovascular death and heart failure hospitalization in adults with chronic heart failure and treats symptomatic heart failure in children aged one year and older.

Entresto pairs two medicines in one tablet. Sacubitril blocks neprilysin, the enzyme that breaks down natriuretic peptides, the body's natural signals

Cosentyx (secukinumab) is an interleukin-17A inhibitor from Novartis for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa. It blocks a key cytokine that sustains inflammation in skin, joints, and spine.

Secukinumab is a recombinant human antibody given by subcutaneous injection. It binds the pro-inflammatory cytokine interleukin-17A and prevents it fr

Trametinib (Mekinist) is a MEK inhibitor used to treat certain melanomas, lung cancers, thyroid cancers, and other solid tumors with BRAF V600 mutations. It blocks the MEK protein, which is part of the same growth pathway as BRAF. It is used alone or in combination with dabrafenib.

Trametinib blocks the action of MEK proteins, which are part of a chain of signals that tell cancer cells to grow and divide. In certain cancers with

Travatan (travoprost) is a prostaglandin analogue eye drop from Novartis that lowers raised intraocular pressure. In the European Union it is used in adults with ocular hypertension or open-angle glaucoma, and in children from 2 months of age with ocular hypertension or paediatric glaucoma.

Travoprost is an eye drop taken once daily. It belongs to the prostaglandin analogue family and works by improving the drainage of aqueous humour, the